D-Index & Metrics Best Publications
Klaus-Michael Debatin

Klaus-Michael Debatin

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Biology and Biochemistry D-index 90 Citations 52,748 409 World Ranking 1051 National Ranking 79
Medicine D-index 101 Citations 48,299 466 World Ranking 3506 National Ranking 144

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cancer
  • Internal medicine

Klaus-Michael Debatin focuses on Apoptosis, Cancer research, Programmed cell death, Fas receptor and Caspase. His work deals with themes such as Cytotoxic T cell, Signal transduction, Cell biology and Cell culture, which intersect with Apoptosis. His Cancer research study also includes

  • Immunology and related Hypoxia,
  • Inhibitor of apoptosis that intertwine with fields like Pancreatic cancer.

His work carried out in the field of Programmed cell death brings together such families of science as Tumor necrosis factor alpha, Cancer, Internal medicine and Endocrinology. His Fas receptor research includes themes of Fas ligand, Autocrine signalling, Molecular biology, Neuroblastoma and Caspase 8. His Caspase study incorporates themes from Cytochrome c and Mitochondrion.

His most cited work include:

  • Two CD95 (APO‐1/Fas) signaling pathways (2781 citations)
  • Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy (1632 citations)
  • Monoclonal antibody-mediated tumor regression by induction of apoptosis (1632 citations)

What are the main themes of his work throughout his whole career to date?

Klaus-Michael Debatin mostly deals with Apoptosis, Cancer research, Immunology, Programmed cell death and Internal medicine. His research in Apoptosis intersects with topics in Cytotoxic T cell and Signal transduction, Cell biology. His study looks at the relationship between Cancer research and topics such as XIAP, which overlap with Inhibitor of apoptosis.

Klaus-Michael Debatin has researched Immunology in several fields, including Stem cell and Transplantation. His Programmed cell death research is multidisciplinary, relying on both Cancer cell, Tissue homeostasis, In vivo and Tumor necrosis factor alpha. His Internal medicine research integrates issues from Diabetes mellitus, Endocrinology and Oncology.

He most often published in these fields:

  • Apoptosis (45.51%)
  • Cancer research (41.32%)
  • Immunology (28.14%)

What were the highlights of his more recent work (between 2015-2021)?

  • Cancer research (41.32%)
  • Internal medicine (20.81%)
  • Apoptosis (45.51%)

In recent papers he was focusing on the following fields of study:

The scientist’s investigation covers issues in Cancer research, Internal medicine, Apoptosis, Immunology and Programmed cell death. His study in Cancer research is interdisciplinary in nature, drawing from both Cell culture, Neuroblastoma, Cell and Leukemia. His biological study spans a wide range of topics, including Endocrinology and Oncology.

Klaus-Michael Debatin regularly ties together related areas like In vivo in his Apoptosis studies. His research integrates issues of Hematopoietic stem cell transplantation and Severe combined immunodeficiency in his study of Immunology. Klaus-Michael Debatin has researched Programmed cell death in several fields, including In vitro and Asparaginase.

Between 2015 and 2021, his most popular works were:

  • Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. (1421 citations)
  • Childhood cancer predisposition syndromes : A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology (85 citations)
  • miR-146a-mediated suppression of the inflammatory response in human adipocytes (51 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • Internal medicine

His primary areas of study are Cancer research, Internal medicine, Apoptosis, Immunology and Cell. His Cancer research study incorporates themes from Protein kinase B, DNA damage, N-Myc, DNA repair and PI3K/AKT/mTOR pathway. His work on Internal medicine is being expanded to include thematically relevant topics such as Endocrinology.

His Apoptosis study frequently intersects with other fields, such as Bioinformatics. His studies deal with areas such as Vincristine and Haematopoiesis as well as Immunology. His Programmed cell death study integrates concerns from other disciplines, such as In vitro, Gene knockdown and Blot.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Two CD95 (APO‐1/Fas) signaling pathways

Carsten Scaffidi;Simone Fulda;Anu Srinivasan;Claudia Friesen.
The EMBO Journal (1998)

3882 Citations

Monoclonal antibody-mediated tumor regression by induction of apoptosis

Bernhard C. Trauth;Christiane Klas;Anke M.J. Peters;Siegfried Matzku.
Science (1989)

2734 Citations

Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy

S. Fulda;Klaus-Michael Debatin.
Oncogene (2006)

2631 Citations

Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)

Jens Dhein;Henning Walczak;Caroline Bäumler;Klaus-Michael Debatin.
Nature (1995)

1978 Citations

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Lorenzo Galluzzi;Ilio Vitale;Stuart A. Aaronson;John M. Abrams.
Cell Death & Differentiation (2018)

1882 Citations

Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity

F. Rieux-Laucat;F. Le Deist;C. Hivroz;I. A. G. Roberts.
Science (1995)

1864 Citations

Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells.

Claudia Friesen;Ingrid Herr;Ingrid Herr;Peter H. Krammer;Klaus Michael Debatin;Klaus Michael Debatin.
Nature Medicine (1996)

1491 Citations

Cellular stress response and apoptosis in cancer therapy

Ingrid Herr;Klaus-Michael Debatin.
Blood (2001)

1096 Citations

Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.

Simone Fulda;Wolfgang Wick;Michael Weller;Klaus Michael Debatin;Klaus Michael Debatin.
Nature Medicine (2002)

952 Citations

Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells.

F. Leithauser;J. Dhein;G. Mechtersheimer;K. Koretz.
Laboratory Investigation (1993)

947 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Klaus-Michael Debatin

Simone Fulda

Simone Fulda

Goethe University Frankfurt

Publications: 257

Peter H. Krammer

Peter H. Krammer

German Cancer Research Center

Publications: 180

Guido Kroemer

Guido Kroemer

Sorbonne University

Publications: 155

Martin Wabitsch

Martin Wabitsch

University of Ulm

Publications: 123

Lorenzo Galluzzi

Lorenzo Galluzzi

Cornell University

Publications: 114

Douglas R. Green

Douglas R. Green

St. Jude Children's Research Hospital

Publications: 87

Henning Walczak

Henning Walczak

University College London

Publications: 78

Marcus E. Peter

Marcus E. Peter

Northwestern University

Publications: 74

Klaus Schulze-Osthoff

Klaus Schulze-Osthoff

University of Tübingen

Publications: 69

Peter T. Daniel

Peter T. Daniel

Max Delbrück Center for Molecular Medicine

Publications: 67

Frédéric Rieux-Laucat

Frédéric Rieux-Laucat

Imagine Institute of Genetic Diseases

Publications: 66

John C. Reed

John C. Reed

Sanford Burnham Prebys Medical Discovery Institute

Publications: 61

Michael J. Lenardo

Michael J. Lenardo

National Institutes of Health

Publications: 61

Shigekazu Nagata

Shigekazu Nagata

Osaka University

Publications: 61

Andreas Strasser

Andreas Strasser

Walter and Eliza Hall Institute of Medical Research

Publications: 60

Andrew R. Gennery

Andrew R. Gennery

Boston Children's Hospital

Publications: 59

Something went wrong. Please try again later.